You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 6,087,172


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,087,172
Title: Ribozymes targeted to human IL-15 mRNA
Abstract:Enzymatic RNA molecules which cleave mRNA encoding IL-15, are provided. The constructs of the invention include regulatory regions for expression in cells, cell lines, or transgenic non-human animals. The ribozymes of the invention are directed against IL-15 mRNA and are useful in treating rheumatoid arthritis.
Inventor(s): Veerapaneni; Dange (San Diego, CA), Hamanaka; Shoji (Kanagawa, JP), Nozawa; Iwao (Tokyo, JP)
Assignee: Hisamitsu Pharmaceutical Co., Inc. (Saga, JP)
Application Number:08/962,503
Patent Claims:1. An isolated enzymatic RNA molecule which specifically cleaves human mRNA encoding interleukin-15 (IL-15).

2. The enzymatic RNA molecule of claim 1, wherein said enzymatic RNA molecule is a hammerhead ribozyme.

3. The enzymatic RNA molecule of claim 1, wherein said enzymatic RNA molecule is selected from the group consisting of a hairpin, hepatitis delta virus, group I intron, VS RNA, tetrahymena, and a RNAse P RNA motif.

4. The enzymatic RNA molecule of claim 1, wherein said enzymatic RNA comprises at least 5 bases complementary to said interleukin 15 (IL-15) mRNA.

5. The enzymatic RNA of claim 4, wherein said enzymatic RNA comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10.

6. The enzymatic RNA molecule of claim 1, wherein said enzymatic RNA molecule comprises phosphorothioate or methyl phosphonate-linked analogues.

7. The enzymatic RNA molecule of claim 5, wherein said RNA molecule further comprises a stem loop structure.

8. The enzymatic RNA molecule of claim 5, wherein said enzymatic RNA molecule further comprises a 5' end modification.

9. The enzymatic RNA molecule of claim 8, wherein said 5' end modification is a 5' trimethylguanosine cap.

10. An expression vector comprising a nucleic acid encoding the enzymatic RNA molecule of claim 1.

11. The expression vector of claim 10, further comprising a promoter operably associated with the enzymatic RNA.

12. The expression vector of claim 10, wherein the enzymatic RNA molecule comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10, or any combination thereof.

13. A mammalian cell comprising an enzymatic RNA molecule of claim 1, wherein said cell is in vitro.

14. The cell of claim 14, wherein said cell is a human cell.

15. The cell of claim 15, wherein the enzymatic RNA molecule comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10, or any combination thereof.

16. A method for inhibiting IL-15 production in a cell in vitro, the method comprising: administering to the cell an amount of an enzymatic RNA molecule sufficient to cleave specifically mRNA encoding interleukin-15 (IL-15) thereby inhibiting IL-15 production.

17. The method of claim 16, further comprising administering an enzymatic RNA molecule which specifically cleaves TNF-.alpha..

18. The method of claim 16, wherein the enzymatic RNA molecule comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10, or any combination thereof.

19. A composition comprising:

a pharmaceutically acceptable carrier; and

an isolated enzymatic RNA molecule which specifically cleaves human mRNA encoding interleukin-15 (IL-15).

20. The composition of claim 19, wherein the enzymatic RNA molecule comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10, or any combination thereof.

Details for Patent 6,087,172

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2039-02-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2039-02-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.